Association between active pulmonary tuberculosis and circulating microRNAs: a preliminary study from Turkey

Fatma KALAYCI YÜKSEK1,2,*, Cenk KIĞ1, Gönenç ORTAKÖYLÜ1, Meltem UZUN1

1Department of Medical Microbiology, Faculty of Medicine, İstanbul University, İstanbul, Turkey
2Department of Medical Microbiology, Faculty of Medicine, Istanbul Yeni Yüzyıl University, Istanbul, Turkey

Background/aim: Tuberculosis is a public health problem that still remains significant. For prevention, diagnosis, and treatment of tuberculosis more effective novel biomarkers are needed. MicroRNAs can regulate innate and adaptive immune responses, alter host-pathogen interactions, and affect progression of diseases. The relationship between microRNA expression and active pulmonary tuberculosis (APT) has not yet been investigated in the Turkish population. We aimed to test the potential diagnostic value of some microRNAs whose levels were previously reported to be altered in APT patients.

Materials and methods: Using two different references (U6 and miR-93), we compared the expression levels of potentially important microRNAs in serum of APT patients with healthy individuals using quantitative polymerase chain reaction (qPCR).

Results: miR-144 expression level was down-regulated in APT patients when either U6 or miR-93 was used for normalization. When data was normalized with miR-93, a statistically significant decrease in miR-125b (0.8 fold) and miR-146a (0.7 fold) expression levels were observed, while no differences were detected for U6. The receiver operating characteristic suggested that miR-144 may be a candidate biomarker for discriminating APT patients and controls (p < 0.05) both for U6 and miR-93.

Conclusion: These findings suggest that miR-144 can have potential as a biomarker for APT. Using a single reference may be misleading in evaluation of microRNA expression. U6 and miR-93 can be used in combination as references for normalization of serum microRNA expression data.

Key words: Circulating-microRNAs, active pulmonary tuberculosis, biomarker, Mycobacterium tuberculosis

1. Introduction

Mycobacterium tuberculosis (Mt), the causative agent of tuberculosis, is estimated to be responsible for ten million new cases of tuberculosis (TB) and approximately 1.5 million deaths in 2018 throughout the world. Tuberculosis is still one of the top 10 causes of death worldwide. Early diagnosis of TB infection is important to prevent the spread of disease and for its’ treatment. In addition to the PCR-based molecular tests such as GenXpert (Cepheid), Mt culture is currently accepted as the gold standard for TB diagnosis. Mt isolation is time-consuming and microscopic analysis can yield subjective results. However, sensitive molecular diagnostic techniques such as PCR are only available in well-equipped laboratories. Due to the limited access to molecular diagnostic tools, simpler methods that allow for detection of stably expressed novel biomarkers are required.

In recent years, microRNAs (miRNAs) have been investigated for their potential role in the area of TB diagnosis. MicroRNAs are small noncoding RNA molecules which are known to modulate in RNA interference and which affect to protein translation or decay mRNA. It is known that miRNAs effect epigenetic mechanisms affecting by DNA methyltransferases, histone deacetylases, and histone methyltransferases. They also play roles in DNA methylation, RNA, and histone modifications. The interactions of miRNAs and epigenetic mechanisms are reported as very important for...
modulating cell proliferation, apoptosis, differentiation, and regulation of immune response mechanisms [4–6]. Therefore these molecules are shown to be involved in modulating various biological and pathological processes such as inflammation, cancer, and infectious diseases [7–9]. More importantly, miRNAs are found to be stable in serum and plasma samples which are suitable for long-term storage. In the last decade, a number of researchers have reported that changes in the miRNA expression profiles in bodily fluids can reflect TB pathologies and immunological modulation [6,10–34].

Despite their potential in TB diagnosis, association between miRNA levels and TB infection has not been investigated in Turkish patients to date. In this respect, we aimed to compare the changes in the serum miRNA levels between TB patients and the control group. Eleven miRNAs had been selected to be tested for their diagnostic potential based on a literature survey analysis. These miRNAs were reported to show altered expression during TB infection as well as being involved in the regulation of inflammatory responses against TB [12–34]. The roles of these miRNAs have been summarized in Table 1 [35–38].

It is well known that normalization of data against a reliable reference is the most critical step of RT-qPCR experiments. Considering that some researchers reported variations in the most commonly used U6 reference [39,40], we also aimed to include a second alternative reference. Some researchers suggested alternative references for normalization in TB studies such as miR-16 [12], MammU6, RNU44, and RNU48 [16], let-7 [41]. However, as U6 has been used in majority of studies [14,17,23,25], in this study U6 is preferred for normalization. Moreover, Barry et al. reported that significant variability in miRNA levels across Australian and Chinese populations, independent of disease status. They showed that miR-93 was a suitable reference for normalizing miRNA in plasma of TB patients [42]. Therefore, we used more than one reference to be able to provide more reliable data.

2. Materials and methods

2.1. Study design

We performed a literature survey by reviewing 23 articles which investigated the changes in miRNA expression profiles in TB patients from around the world (Table 2) [12–34]. Among the differentially expressed miRNAs, the most frequently reported and clinically confirmed ones were selected such as miR-29, miR-21, miR-146a, miR-223, miR-142, miR-125b, miR-144, miR-155, miR-99, miR-361, and miR-582-5p (Table 2) for testing in a study group consisting of 20 TB patients and 20 healthy controls from Turkey.

2.2. Ethics statement

This study was performed in accordance with guidelines of the Ethics Committee of Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul (Approval 2016/60). Informed consent was obtained from all participants prior to beginning the study.

2.3. Human subjects

A total of 40 participants were recruited in this study. Twenty patients with active pulmonary TB who presented to “Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul” between September 2017 and May 2018 were included in the study [5 females and 15 males; the median age of active pulmonary TB patients was 34.50 (22.50–38.50)]. Eligibility for patients’ entry into the study included the presence of the typical symptoms for pulmonary TB and M. tuberculosis positive culture test results. Patients who had diabetes, cancer, and other pulmonary diseases or co-infection with other pathogens

| MiRNAs   | The roles                                                                 |
|----------|---------------------------------------------------------------------------|
| miR-29a  | The inhibition of interferon-γ                                            |
| miR-21   | The suppression of IL-1β and increasing of IL-10                           |
| miR-146a | Induction of intracellular growth of bacilli, the inhibition of TNF-α, IL-1β, and IL-6 |
| miR-223  | The suppression of apoptosis and inhibition of IL-6                        |
| miR-142  | The suppression of M. tuberculosis phagocytosis                           |
| miR-125b | The reduction of inflammatory responses via TNF-α                          |
| miR-144  | Inhibition of interferon-γ ,TNF-α, and T cell proliferation              |
| miR-155  | Promotes Th17 differentiation and Interferon-γ production in CD4+ and CD8+ T cells and affecting of apoptosis |
| miR-99   | The suppression of pro-inflammatory cytokine production in dendritic cells |
| miR-361-5p| Targets SP-1 transcription factor (SP1) that is defined as a key signaling pathway for IL-10 expression in the lung |
| miR-582-5p| The inhibition of monocyte apoptosis                                       |
Table 2. MiRNAs associated with tuberculosis in our literature review.

| MiRNAs  | Serum                  | Plasma          | Sputum               | PBMC*                   | PFMC*                   | CSF*                   | T Cells                  | Whole blood | Neutrophil | Monocytes and macrophages |
|---------|------------------------|-----------------|----------------------|-------------------------|-------------------------|-------------------------|--------------------------|--------------|-------------|----------------------------|
| miR-29a | Fu et al., 2011 [14]   | Barry et al., 2018 [16] | Fu et al., 2011 [14] | Pan et al., 2017 [20]   | Spinning et al., 2013 [21] | Pan et al., 2017 [20] | Kleinsteuber et al., 2013 [26] | Fu et al., 2014 [27] | Latorre et al., 2015 [28] |
| miR-21  | Barry et al., 2018 [16] | Xu et al., 2013 [22] | Wang et al., 2011 [23] | Wu et al., 2014 [24]    |                         |                         | Kleinsteuber et al., 2013 [26] |             |             |                             |
| miR-146a| Fu et al., 2011 [14]   | Barry et al., 2018 [16] | Spinelli et al., 2013 [21] | Spinning et al., 2013 [21] |                         |                         |                          |             |             |                             |
| miR-223 | Wang et al., 2011 [23] | Spinning et al., 2013 [21] | Spinelli et al., 2013 [21] |                         |                         |                         | Xi et al., 2015 [29] |             |             |                             |
| miR-142 | Spinning et al., 2013 [21] |                         |                         |                         |                         |                         | Kleinsteuber et al., 2013 [26] |             |             |                             |
| miR-125b| Fu et al., 2011 [14]   | Yi et al., 2012 [31]  |                         |                         |                         |                         | Zhou et al., 2016 [13] |             |             |                             |
| miR-144 | Lv et al., 2016 [17]   | Ndzi et al., 2019 [19] | Lv et al., 2016 [17]  | Liu et al., 2011 [25]   | Spinning et al., 2013 [21] |                         | Zhou et al., 2016 [13] |             |             |                             |
| miR-155 | Fu et al., 2011 [14]   | Ndzi et al., 2019 [19] |                         | Spinning et al., 2013 [21] |                         |                         | Huang et al., 2015 [30] |             |             |                             |
| miR-99b | Barry et al., 2018 [16] | Yi et al., 2012 [31]  |                         |                         |                         |                         | van Rensburg et al., 2018 [32] |             |             |                             |
| miR-361-5p| Qi et al., 2012 [12]   | Ndzi et al., 2019 [19] |                         |                         |                         |                         | Latorre et al., 2015 [28] |             |             |                             |
| miR-582-5p| Fu et al., 2011 [14]   | Yi et al., 2012 [31]  |                         |                         |                         |                         | Liu et al., 2013 [34] |             |             |                             |

*PBMC: peripheral blood mononuclear cells, PFMC: pleural fluid mononuclear cells, CSF: cerebrospinal fluid.
and/or receiving antituberculosis treatment were excluded [14,27,31]. Twenty healthy subjects (15 males and 5 females) free of active or latent TB infection and who did not display any clinical symptoms of any other infectious or noninfectious diseases were recruited as controls [the median age of controls was 30 (28–35)]. A questionnaire was verbally administered to healthy controls and those who declared not having a history of tuberculosis were included in this study. Prior exposure of healthy individuals to TB was not further investigated by using QuantiFERON-TB Gold (QFT) and/or purified protein derivative (PPD) tests. None of the participants had received any drugs at the time of blood collection. No significant difference was found between the two groups, with respect to gender, age, and smoking distribution (Table 3).

### 2.4. RNA extraction and quantitative PCR

Blood sample (~5 mL) was drawn into a sterile polyolefin resin tube without anticoagulant for RNA isolation. Serum separation and RNA extraction were performed within 2 h after blood collection. RNA extraction from serum samples was performed using the mirCURY RNA isolation kit—Biofluids (Exiqon, Denmark) according to manufacturer’s instructions. RNA quality and concentration were determined with a NanoDrop 2000 spectrophotometer Thermo Scientific (Waltham, USA). Reverse transcription was carried out using miRCURY LNA Universal TR microRNA PCR kit (Exiqon, Denmark) according to the manufacturer’s instructions and reactions were performed in a thermal cycler (42 °C for 60 min. and 95 °C for 5 min). After reverse transcription step, cDNAs were diluted to 1/40.

Quantitative PCR reactions were carried out using miRCURY LNA Universal RT microRNA PCR kit in a BIORAD instrument (Bio-Rad, Hercules, CA, USA) according to the instructions of the manufacturer. PCR conditions were as follows: 95 °C for 10 min, followed by 40 cycles at 95 °C for 10 s and 60 °C for 1 min. Total PCR volume was 10 µL. Normalization was performed separately using both U6 small nuclear RNA level and miR-93 levels. Ct values over 40 were not considered significant. The experiments were conducted in duplicates and the results were presented as fold change for each miRNA. Calculations were made using the \(2^{-\Delta\Delta CT} \) method. Sensitivity and accuracy of the protocol were tested at different levels by performing melting curve analysis, using spike RNA as control or amplification curves of serial dilutions for the target miRNAs. Primer sequences can be provided upon request.

### 2.5. Statistical analysis

In order to calculate the sample size, priori power analysis was performed. Power analysis was performed under G*Power 3.1.\(^2\) Shapiro–Wilk test was used for assessing whether the variables follow normal distribution or not. According to the normality test results, Mann–Whitney U test was used in comparison between two groups. Pearson Chi-square test and Fisher’s exact test were used for comparing categorical variables. In order to evaluate the diagnostic accuracy, we used receiver operating characteristic (ROC) curve analysis. SPSS (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, v: 21.0, Armonk, NY: IBM Corp.) and MedCalc v: 12.3.0.0 were used for statistical analysis and a p-value < 0.05 was considered statistically significant. The area under the curve (AUC) and 95% confidence intervals (CI) were calculated for specificity and sensitivity. For ROC analysis we applied the generally accepted criteria, values between

---

\(^{2\text{G}}\)Power (2020). [online]. Website http://www.gpower.hhu.de/ [accessed 21 July 2020].

---

| Table 3. Characteristics of participants. |
|-------------------------------------------|
|                                           |
| Patient group (n = 20)                    |
| Healthy control group (n = 20)            |
| **p-value**                               |
| **Age (years)**                           |
| Median [first IQ-third IQ]               |
| 34.50 [22.50–38.50]                      |
| 30 [28–35]                               |
| 0.758\(^{a}\)                            |
| **Sex (%)**                               |
| Female                                    |
| 5 (25%)                                   |
| 5 (25%)                                   |
| >0.99\(^{b}\)                            |
| Male                                      |
| 15 (75%)                                  |
| 15 (75%)                                  |
| >0.99\(^{c}\)                            |
| **Smoker (%)**                            |
| Positive                                  |
| 16 (80%)                                  |
| 17 (85%)                                  |
| >0.99\(^{d}\)                            |
| Negative                                  |
| 4 (20%)                                   |
| 3 (15%)                                   |
| >0.99\(^{d}\)                            |
| **Sex (%)**                               |
| Female                                    |
| 5 (25%)                                   |
| 5 (25%)                                   |
| >0.99\(^{b}\)                            |
| Male                                      |
| 15 (75%)                                  |
| 15 (75%)                                  |
| >0.99\(^{b}\)                            |
| **Smoker (%)**                            |
| Positive                                  |
| 16 (80%)                                  |
| 17 (85%)                                  |
| >0.99\(^{f}\)                            |
| Negative                                  |
| 4 (20%)                                   |
| 3 (15%)                                   |
| >0.99\(^{f}\)                            |

\(^{a\text{ Mann–Whitney U test}},^{b\text{ Pearson Chi-Square test}},^{c\text{ Fisher’s Exact test}}\)
90%–100% are accepted excellent, 80%–90% good, 70%–80% fair, 60%–70% poor, and 50%–60% bad (or failed) in general.

3. Results

Based on our literature survey (Table 2) we have selected 11 miRNAs for evaluation of their diagnostic potential in TB patients from Turkey. For this purpose, we compared the expression levels of these target miRNAs between patients and the control group via qPCR as explained under the materials and methods section.

Although no reliable reference has been proposed for normalization of circulating miRNAs, U6 and miR-93 were previously used as endogenous controls due to their relatively stable expression levels in TB patients [14,18,31,42]. Thus, both U6 and miR-93 references for normalization of miRNA expression data were included in this study. The Ct values for U6 and miR-93 examined in tuberculosis and healthy control groups were shown in Figure 1.

In agreement with previously reported data, it was found that the expression levels of miR-29, miR-21, miR-146a, miR-223, miR-142, miR-125b, miR-99, miR-361, and miR-582-5p were altered in TB patients as seen in Table 4. However, only the changes in miR-144 expression level (–0.8 fold, p < 0.05) were found to be statistically significant when data was normalized against U6 expression level (Figures 2a and 2b).

When the levels of the target miRNAs in serum were normalized by miR-93, statistically significant changes were detected in the expression levels of miR-144 (–0.9, p < 0.05), miR-125b (–0.8, p < 0.05) and miR-146a (–0.7, p < 0.05). No significant difference was detected in the expression levels of other miRNAs (Table 5).

However, when the expression data were normalized by both U6 and miR-93 only the expression level of miR-144 was found to be statistically significant (–0.8; p < 0.05 and –0.9; p < 0.05 respectively) (Figure 2b). Hence, it was decided that only miR-144 was suitable for further analysis.

Table 4. Fold change distributions in miRNA expression levels when data normalized against U6 RNA *(p: 0.017).

| miRNAs      | Fold changes in patients with active pulmonary TB compared to healthy controls |
|-------------|--------------------------------------------------------------------------------|
| miR-29a     | –0.52                                                                          |
| miR-21      | –0.20                                                                          |
| miR-146a    | –0.61                                                                          |
| miR-223     | 0.13                                                                           |
| miR-142     | –0.19                                                                          |
| miR-125b    | –0.69                                                                          |
| miR-144     | –0.86*                                                                         |
| miR-155     | –0.13                                                                          |
| miR-99b     | –0.24                                                                          |
| miR-361-5p  | 0.20                                                                           |
| miR-582-5p  | –0.13                                                                          |

Figure 1. The Ct values of U6 and miR-93 in patient and healthy control groups.

In the next step, the diagnostic potential of miR-144 was evaluated by ROC analysis. In order to test the potential of both references, we also compared the results obtained from normalization by U6 or miR-93 separately. Our findings demonstrated that miR-144 could distinguish active pulmonary TB from controls with an AUC (the area under the curve) of 0.72 (95 % CI 0.560–0.880, p: 0.017) (Figure 3), based on data obtained from normalization with U6. Similarly, when data from miR-93 normalization was used for ROC analysis, miR-144 could discriminate active pulmonary TB from controls with an AUC of 0.79 for miR-144 (95 % CI 0.644–0.936, p: 0.002) (Figure 3). Suggesting that miR-144 can be a candidate for discriminating the active TB group from the healthy controls.

Moreover, we also determined the diagnostic potential of miR-146a and miR-125b by ROC analysis. Our findings suggested that miR-146a distinguish active pulmonary pulmonary...
TB from healthy controls with an AUC of 0.69 (95% CI 0.530–0.865, p:0.033) and miR-125b distinguish active pulmonary TB from healthy controls with an AUC of 0.70 (95% CI 0.533–0.867, p: 0.03) based on data provided from normalization with miR-93.

4. Discussion

Tuberculosis is a global health problem with high rates of mortality and morbidity. WHO reported that TB is one of the top causes of death worldwide. Rapid and accurate diagnosis of TB is important to prevent the spread of this disease. However, molecular diagnostic techniques (PCR, Western Blot, microarray, etc.) are only available in a small number of laboratories. Due to the limited access to the molecular diagnostic tools easier methods that allow for detection of stably expressed novel biomarkers are required for diagnosis and prognosis of TB [1–3].

Detection of stable miRNAs in bodily fluids has opened new avenues for their usage as biomarkers for a number of diseases including TB [7,8,12–34,43,44]. Recent studies also demonstrated that miRNAs can have immune-modulatory roles. For instance, a number of miRNAs were shown to be involved in host-pathogen interactions and inflammatory responses [6,7,9,35–37]. Tuberculosis is defined as granulomatous inflammation which involves inflammatory cells and various host factors. These inflammatory cells can secrete miRNAs into the serum [6,12,16] and recent findings suggest that these circulating miRNAs can serve as useful clinical biomarkers [9,12–34]. A number of different miRNAs are reported to be associated with TB infections and some of the most important ones are summarized in Table 2. Despite a wealth of information on this subject, the association between the changes of serum miRNA levels during TB has not been investigated in Turkish patients so far.

Selection of proper references for normalization is crucial for accurate analysis of qPCR data. U6 RNA is the widely accepted reference for normalization of miRNA expression levels [14,18,31,42]. However, U6 expression levels have also shown to vary depending on the types of diseases, technical variations or personal characteristics [39,40]. MiR-93 has been recently suggested as an alternative reference RNA by Barry et al. [42]. However, some studies also reported conflicting results for miR-93 [14]. The discrepancies may originate from the procedures used for obtaining, handling and storing the specimens. Some other studies also suggest variations in miRNA levels based on ethnical background [16,42,45,46]. In this sense, to be able to get more reliable and accurate results, we have also included miR-93 for data normalization in addition to U6 RNA.

Firstly, we analyzed our findings by normalizing data against the widely used U6 RNA levels. In accordance with the previous reports [14,16,21,31], we found that serum levels of miR-144 were significantly down-regulated (−0.8 fold, p < 0.05) in active TB patients when compared to healthy group (Table 4). However, despite the obvious

| miRNAs  | Fold changes in patients with active pulmonary TB compared to healthy controls |
|---------|--------------------------------------------------------------------------------|
| miR-29a | −0.62                                                                          |
| miR-21  | −0.57                                                                          |
| miR-146a| −0.79*                                                                         |
| miR-223 | −0.40                                                                          |
| miR-142 | −0.57                                                                          |
| miR-125b| −0.83*                                                                         |
| miR-144 | −0.92*                                                                         |
| miR-155 | −0.53                                                                          |
| miR-99b | −0.60                                                                          |
| miR-361-5p| −0.36                                                                       |
| miR-582-5p| −0.54                                                                       |

Table 5. Fold change distributions in miRNA expression levels when data normalized against miR-93 (*p: 0.033, *p: 0.03, *p: 0.002).
increases in the mean expression levels of miR-29, miR-21, miR-146a, miR-142, miR-125b, miR-155, miR-99 and miR-582-5p in TB patients, these changes were not found to be statistically significant. Normalization of data against miR-93, yielded significant changes in the expression levels of miR-144 (–0.9, p < 0.05), miR-125b (–0.8, p < 0.05) and miR-146a (–0.7, p < 0.05) (Table 5). When we normalized the expression data both for U6 and miR-93, only the expression level of miR-144 was found to be statistically significant (–0.8; p < 0.05 and –0.9; p < 0.05 respectively) (Table 4 and Table 5). In agreement with the previous observations by different research groups, miR-144 levels were frequently reported to be altered in TB patients (Table 2). For instance, miR-144 was previously shown to be expressed in T cells and this miRNA is proposed as a potential biomarker candidate for TB diagnosis [13,17,25].

In general, despite the slight discrepancies, miRNA expression patterns were found to be very similar when normalization was made either against U6 or miR-93 (Table 4 and Table 5). Thus, usage of both U6 and miR-93 as two different references seems to be a suitable and reliable approach for data normalization of miRNA expression. Accordingly, Barry et al. and Barry et al. suggested that miR-93 could be used as an alternative reference miRNA for data normalization [18,42].

The receiver operating curve (ROC) is a tool which can be employed for testing the performance and potential of biomarker candidates. Hence, we assessed the diagnostic potential of miR-144 by ROC analysis. Since both U6 and miR-93 were used for normalization, we also compared the ROC data separately for these two different references. Based on data obtained from normalization with U6, we showed that miR-144 could distinguish active pulmonary TB from healthy participants with an AUC (the area under the curve) of 0.72 (95 % CI 0.560–0.880, p: 0.017). Similarly, when data from miR-93 normalization was used for ROC analysis, miR-144 could discriminate active pulmonary TB from healthy controls with an AUC of 0.79 for miR-144 (95 % CI 0.644–0.936, p: 0.002) (Figure 3). In agreement with previous studies [13,17,25], our findings suggest that miR-144 can hold the potential to be a candidate for discriminating the active TB group from the healthy participants.

As mentioned earlier, in addition to miR-144, the expression levels of miR-125b and miR-146a were also altered in TB patients when the normalization was performed with miR-93 (Table 5). Some researchers pointed that miR-144 has a potential as a biomarker for TB [13,17,25], it was reported that miR-125b may be used for identifying TB [13,14,31,33]. In addition to these results, other reports have concluded that miR-146a is related TB pathologies [14,16,18,21] consistent with these results. It appears that miRNA expression levels differ greatly according to both ethnic groups and the clinical samples examined [16,42,45,46]. For this reason, it is necessary to determine the miRNA variability on the basis of ethnicity and confirm clinical samples which are suitable for TB diagnosis.

In addition to these results, we sought to get a preliminary view of the possible pathways that these miRNAs might be involved. In this sense, we performed a target gene prediction analysis using online bioinformatics tools1,2.

In agreement with the previous reports [13,25], our analysis also revealed that genes (miRNAs) involved in toll-like receptor signaling pathway, Jak-STAT signaling pathway, NOD-like receptor signaling pathway, apoptosis, and pro-inflammatory cytokines might have been among the high-priority targets for these miRNAs (Figure 4). Unfortunately, we were not able to experimentally validate the changes in these target pathways.

In conclusion, we found that the expression level of miR-144 was lower in serum samples of TB patients when compared to healthy controls. In contrast, Liu et al., reported that miR-144* was up-regulated in T cells of active TB patients compared with healthy controls [25]. Similarly, Lv et al. showed that miR-144 levels of TB patients in sputum and serum samples were higher than healthy controls when measured before treatment for TB. They also reported that sputum and serum miR-144 levels were significantly lower in TB patients after treatment [17]. In addition, Spinelli et al. reported that the expression levels of miR-144 were altered in PBMCs and pleural fluid mononuclear cells [21]. However, we could not confirm an increase in the expression of miR-144 as suggested by Lv et al. [17], Liu et al. [25]. In general, our observations were in line with the previous reports [13,17,25]. The changes in the miR-144 expression levels seem to have a potential for TB diagnosis. Since there is no data available on the changes in miRNA profiles of TB patients from Turkey, we could not compare our findings with findings from the Turkish population.

In this sense, ethnicity can also play a role in these discrepancies. However, it will not be possible to draw accurate conclusions with data obtained from small sample size. We are currently trying to expand our findings in a larger sample size where additional control groups for distinct infectious diseases, noninfectious lung diseases and healthy controls that are free of latent TB infection are included. These points are also the limitations of our study. Today, it is still not clearly understood which underlying

---

1 TarBase v7.0-DIANA TOOLS (2020). [online]. Website http://diana.imis.athena-innovation.gr/DianaTools/index.php. [accessed 21 July 2020].

2 miRDB (2020). MicroRNA target prediction database [online]. Website http://www.mirdb.org/cgi-bin/search.cgi [accessed 09 November 2020].
mechanisms are involved in transition from latent TB to active TB. Some authors reported that active and latent TB could affect similar pathways. At this point, the detection of which miRNAs are different for these diseases is important for clarifying accurate marker(s) for TB. Several studies of miRNA expression levels in serum/plasma and blood cells have been performed that included subjects with active, latent TB, and healthy controls [19,23,27,28]. Fu et al., Ndzi et al., and Wang et al. reported similar miRNA expression trends for miR-29 and miR-451 which were observed in both active and latent TB groups compared to the controls [19,23,27]. Furthermore, miR-29a, miR-29b, miR-29c, miR-451, miR-340, miR-424, miR-361, miR-365, miR-196-5p, miR-144, miR-223, and miR-21 were reported to be upregulated in active TB compared to latent TB group [19,23,27,28] while miR-150-5p and miR-4292 were found to be down-regulated [19,23,27,28]. Therefore, some miRNAs were described to be important for discriminating active TB and latent TB. However, sample size and the use of additional control groups seem to be the limiting factors for validation of these markers. We believe that a whole miRNA profiling study should also be necessary for determining novel miRNA candidates as well as validation of the targets at the mRNA or protein level.

More importantly, comparison of changes before and after treatment can also reveal valuable information. Despite the limitations discussed above, this is the first preliminary study in Turkey which investigated the changes in the miRNA levels in TB patients. We found that miR-144 can be a suitable candidate for its further evaluation as a potential biomarker for TB. We also showed that U6 and miR-93 can be used in combination as reference for normalization of serum miRNA expression data.

Acknowledgment

This study was funded by Istanbul University with project number, 24335. We would like to thank Ayça Pamukcu, Aslı Ceren Macunluoğlu, and Varol Güler better for their valuable support and comments. We gratefully thank Dr Sezer Toprak and Dr Derya Cenger at Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital for analyzing patient’s microbiological tests. We also thank Dr. Michael Hansen for his support in troubleshooting technical difficulties.

Figure 4. Analysis of miRNA (miR-144, miR-146a, and miR-125b) targets in DIANA tools database which are involved in TB response. Genes highlighted in red circles indicate the targets of miR-125b and miR-146a. Genes shown in dark blue circles show putative targets of miR-144, which may indirectly play a role in the pathway (encoded by TNFRSF11A, CIAPIN1, SH3GLB1, and SH2D1B genes). NF-κB is found to be the common target for miR-125b, miR-144, and miR-146a.  

1 TarBase v7.0-DIANA TOOLS (2020). Website http://diana.imis.athena-innovation.gr/DianaTools/index.php [accessed 21 July 2020].  

2 miRDB (2020). MicroRNA target prediction database. Website http://www.mirdb.org/cgi-bin/search.cgi [accessed 09 November 2020].
Conflict of interest
There is no conflict of interest to disclose.

Funding
This study was funded by Istanbul University with project number, 24335.

References

1. Thangappah RBP, Paramasivan CN, Narayanan S. Evaluating PCR, culture & histopathology in the diagnosis of female genital tuberculosis. Indian Journal of Medical Research 2011; 134 (1): 40-46.

2. Honoré-Bouakline S, Vincensini JP, Giacuzzo V, Lagrange PH, Herrmann JL. Rapid diagnosis of extrapulmonary tuberculosis by PCR: impact of sample preparation and DNA extraction. Journal of Clinical Microbiology 2003; 41 (6): 2323-2329. doi: 10.1128/JCM.41.6.2323-2329.2003

3. Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical Microbiology Reviews 2011; 24 (2): 314-350. doi: 10.1128/CMR.00059-10

4. Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomolecular Concepts 2017; 8 (5-6): 203-212. doi: 10.1515/bmc-2017-0024

5. Yao Q, Chen Y, Zhou X. The roles of microRNAs in epigenetic regulation. Current Opinion in Chemical Biology 2019; 51: 11-17. doi: 10.1016/j.cbpa.2019.01.024

6. Tsitsiou E, Lindsay MA. MicroRNAs and the immune response. Current Opinion in Pharmacology 2009; 9 (4): 514-520. doi: 10.1016/j.coph.2009.05.003

7. Abd-El-Fattah AA, Sadik NAH, Shaker OG, Aboutoulth ML. Differential microRNAs expression in serum of patients with lung cancer, pulmonary tuberculosis, and pneumonia. Cell Biochemistry and Biophysics 2013; 67 (3): 875-884. doi: 10.1007/s12013-013-9575-y

8. Aigner A. MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related microRNAs. Journal of Molecular Medicine 2011; 89 (5): 445-457. doi: 10.1007/s00109-010-0716-0

9. Luna JM, Scheel TK, Danino T, Shaw KS, Mele A et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 2015; 160 (6): 1099-1110. doi: 10.1016/j.cell.2015.02.025

10. Köberle V, Pleli T, Schmithals C, Alonso EA, Haupenthal J et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. Plos One 2013; 8 (9): e75184. doi: 10.1371/journal.pone.0075184

11. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annual Review of Biochemistry 2010; 79: 351-379. doi: 10.1146/annurev-biochem-060308-103103

12. Qi Y, Cui L, Ge Y, Shi Z, Zhao K et al. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infectious Diseases 2012; 28 (12): 384-391. doi: 10.1186/1471-2334-12-384

13. Zhou M, Yu G, Yang X, Zhu C, Zhang Z et al. Circulating microRNAs as biomarkers for the early diagnosis of childhood tuberculosis infection. Molecular Medicine Reports 2016; 13 (6): 4620-4626. doi: 10.3892/mmr.2016.5097

14. Fu Y, Yi Z, Wu X, Li J, Xu F. Circulating microRNAs in patients with active pulmonary tuberculosis. Journal of Clinical Microbiology 2011; 49 (12): 4246-4251. doi: 10.1128/JCM.05459-11

15. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G et al. MicroRNA signatures in sera of patients with active pulmonary tuberculosis. The Egyptian Journal of Microbiology 2014; 23 (4): 27-36.

16. Miotto P, Mwangoka G, Valente IC, Norbis L, Sotgiu G et al. MicroRNA signatures in sera of patients with active pulmonary tuberculosis. The Egyptian Journal of Microbiology 2014; 23 (4): 27-36.

17. Lv Y, Guo S, Li XG, Chi JY, Qu YQ et al. Sputum and serum microRNA-144 levels in patients with tuberculosis before and after treatment. International Journal of Infectious Diseases 2016; 43: 68-73. doi: 10.1016/j.ijid.2015.12.014

18. Barry SE, Ellis M, Yang Y, Guan G, Wang X et al. Identification of a plasma microRNA profile in untreated pulmonary tuberculosis patients that is modulated by anti-mycobacterial therapy. Journal of Infection 2018; 77 (4): 341-348. doi: 10.1016/j.jinf.2018.03.006

19. Ndzi EN, Nkenfou CN, Mekue LM, Zentilin L, Tamgue O et al. MicroRNA hsa-miR-29a-3p is a plasma biomarker for the differential diagnosis and monitoring of tuberculosis. Tuberculosis 2019; 114: 69-76. doi: 10.1016/j.tube.2018.12.001

20. Pan D, Pan M, Xu YM. MiR-29a expressions in peripheral blood mononuclear cell and cerebrospinal fluid: diagnostic value in patients with pediatric tuberculosis meningitis. Brain Research Bulletin 2017; 130: 231-235. doi: 10.1016/j.brainresbull.2017.01.013

21. Spinelli SV, Diaz A, D’Attilio L, Marchesini MM, Bogue C et al. Altered microRNA expression levels in mononuclear cells of patients with pulmonary and pleural tuberculosis and their relation with components of the immune response. Molecular Immunology 2013; 53 (3): 265-269. doi: 10.1016/j.molimm.2012.08.008
22. Xu G, Zhang Z, Wei J, Zhang Y, Zhang Y et al. MicroR-142-3p down-regulates IRAK-1 in response to *Mycobacterium bovis* BCG infection in macrophages. Tuberculosis 2013; 93 (6): 606-611. doi: 10.1016/j.tube.2013.08.006

23. Wang C, Yang S, Sun G, Tang X, Lu S et al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. Plos One 2011; 6 (10): e25832. doi: 10.1371/journal.pone.0025832

24. Wu LSH, Lee SW, Huang KY, Lee TY, Hsu PWC et al. Systematic expression profiling analysis identifies specific microRNA-gene interactions that may differentiate between active and latent tuberculosis infection. BioMed Research International 2014; 895179. doi: 10.1155/2014/895179

25. Liu Y, Wang X, Jiang J, Cao Z, Yang B et al. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Molecular Immunology 2011; 48 (9-10): 1084-1090. doi: 10.1016/j.molimm.2011.02.001

26. Kleinsteuber K, Heesch K, Schattling S, Kohns M, Sander-AG. Decreased neutrophil–associated miRNA and increased apoptosis of monocytes by targeting FOXO3. Molecular and Cellular Pediatrics 2014; 18 (3): 503-513. doi: 10.1016/j.mccp.2014.10.064

27. Fu Y, Yi Z, Li J, Li R. Deregulated micro RNA s in CD4+ T cells from individuals with latent tuberculosis versus active tuberculosis. Journal of Cellular and Molecular Medicine 2014; 18 (3): 503-513. doi: 10.1111/jccm.12205

28. Latorre J, Leidinger P, Backes C, Dominguez J, De Souza-Galvão ML et al. A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis. European Respiratory Journal 2015; 45 (4): 1173-1176. doi: 10.1183/09031996.00221514

29. Xi X, Zhang C, Han W, Zhao H, Zhang H et al. MicroRNA-223 is upregulated in active tuberculosis patients and inhibits apoptosis of macrophages by targeting FOXO3. Genetic Testing and Molecular Markers 2015; 19 (12): 650-656. doi: 10.1089/gtmm.2015.0090

30. Huang J, Jiao J, Xu W, Zhao H, Zhang C et al. MiR-155 is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO3. Molecular Medicine Reports 2015; 12 (5): 7102-7108. doi: 10.3892/mmr.2015.4250

31. Yi Z, Fu Y, Ji R, Li R, Guan Z. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. Plos One 2012; 7 (8): e43184. doi: 10.1371/journal.pone.0043184

32. Van Rensburg IC, Du Toit L, Walzl G, Du Plessis N, Loxton AG. Decreased neutrophil–associated microRNA and increased B-cell associated miRNA expression during tuberculosis. Gene 2018; 655: 35-41. doi: 10.1016/j.gene.2018.02.052

33. Wang C, Liu CM, Wei LL, Shi LY, Pan ZF et al. A group of novel serum diagnostic biomarkers for multidrug-resistant tuberculosis by iTRAQ-2D LC-MS/MS and Solexa sequencing. International Journal of Biological Sciences 2016; 12 (2): 246-256. doi: 10.7150/ijbs.13805